Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy
Current Oncology · 2025
DOI: 10.3390/curroncol32090503 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Yunus Emre Altıntaş und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul 34865, Türkiye. Hauptthemen laut MEDLINE: Everolimus, Breast Neoplasms, Androstadienes, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hormone receptor-positive (HR+), HER2− negative metastatic breast cancer (MBC) is the most common subtype of advanced breast cancer. Resistance to endocrine therapy often develops, particularly after CDK4/6 inhibitors. Everolimus, an mTOR inhibitor, may restore hormone sensitivity, but real-world data after CDK4/6 and chemotherapy are limited.
Methods
This retrospective, single-center study included 70 patients with HR+/HER2− MBC who progressed on CDK4/6 inhibitors and at least one line of chemotherapy. All received daily oral everolimus (10 mg) plus exemestane (25 mg). Tumor response was assessed via RECIST v1.1, and survival outcomes were estimated using the Kaplan–Meier method.
Results
Median progression-free survival was 6.6 months and overall survival was 22.6 months. The disease control rate was 88.6%, with 57.1% showing partial response. Fatigue (20%), skin toxicity (8.6%), and stomatitis (5.7%) were the most common adverse events. No grade 3–4 toxicities or discontinuations occurred. No clinical or pathological variables significantly influenced survival.
Conclusions
Everolimus plus exemestane provided meaningful clinical benefit and manageable toxicity in heavily pretreated HR+/HER2− MBC patients. This regimen remains a valid later-line option, particularly in settings with limited access to newer targeted therapies or genomic testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul 34865, Türkiye.
- Department of Medical Oncology, Ümraniye Training and Research Hospital, Istanbul 34760, Türkiye.
ORCID-Profile: Yunus Emre Altıntaş, Oğuzcan Kınıkoğlu, Deniz Işık, Ayberk Bayramgil, Sıla Öksüz, Heves Sürmeli, Nedim Turan, Hatice Odabaş
Zitieren
APA
Altıntaş, Y. E., Kınıkoğlu, O., Işık, D., Batu, A., Bayramgil, A., Niğdelioğlu, B., Özkerim, U., Öksüz, S., Sürmeli, H., Turan, N., & Odabaş, H. (2025). Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy. Current Oncology. https://doi.org/10.3390/curroncol32090503
Vancouver
Altıntaş YE, Kınıkoğlu O, Işık D, Batu A, Bayramgil A, Niğdelioğlu B, et al. Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy. Current Oncology. 2025. doi:10.3390/curroncol32090503
BibTeX
@article{Altnta2025,
author = {Altıntaş, Yunus Emre and Kınıkoğlu, Oğuzcan and Işık, Deniz and Batu, Aziz and Bayramgil, Ayberk and Niğdelioğlu, Büşra and Özkerim, Uğur and Öksüz, Sıla and Sürmeli, Heves and Turan, Nedim and Odabaş, Hatice},
title = {Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32090503}
}
EUVIMED